Created Tue 19th Jan 12:24pm PST by 
frogchop
frogchop 
Will additional FDA approved clinical trials show potential theraputic benefits for MDMA (ecstasy)?
Background: Post-traumatic stress disorder—PTSD—can linger years after someone has experienced or witnessed something extremely upsetting. It may be accompanied by panic attacks, flashbacks, and nightmares, and it can be fiendishly difficult to treat. But experimental types of treatment could soon lend a hand.
In a pilot study, South Carolina psychiatrist Michael Mithoefer is targeting PTSD with a controversial drug: methylenedioxymethamphetamine, or MDMA, commonly known as Ecstasy. He gave MDMA, along with psychotherapy, to 21 participants who had developed treatment-resistant PTSD as a result of experiences with crime or war. Only 15 percent of the MDMA-treated subjects continued to experience PTSD afterward, as opposed to 85 percent of the subjects who received psychotherapy with a placebo. Mithoefer considers the findings especially notable given that 20 of the 21 participants had previously failed to obtain relief from FDA-approved treatments. “The next step is to find out if this can be replicated elsewhere,” he says. The study, sponsored by the Multidisciplinary Association for Psychedelic Studies, was the first FDA-approved trial evaluating MDMA’s therapeutic applications. Additional clinical tests examining MDMA-based treatments for PTSD are under way in Switzerland and Israel.
http://discovermagazine.com/2009/nov/20-treating-agony-with-ecstasy
--------------------------------------------------
Does not include the study cited above, but any other FDA approved clinical trial publishing results in 2010 that show theraputic benefits (not simply safety or dosage levels) will settle as YES. No studies published on FDA approved studies/no studies demonstrating theraputic benefits will settle as NO. Studies outside the US, thus not approved by the FDA will not be considered for settlement.
In a pilot study, South Carolina psychiatrist Michael Mithoefer is targeting PTSD with a controversial drug: methylenedioxymethamphetamine, or MDMA, commonly known as Ecstasy. He gave MDMA, along with psychotherapy, to 21 participants who had developed treatment-resistant PTSD as a result of experiences with crime or war. Only 15 percent of the MDMA-treated subjects continued to experience PTSD afterward, as opposed to 85 percent of the subjects who received psychotherapy with a placebo. Mithoefer considers the findings especially notable given that 20 of the 21 participants had previously failed to obtain relief from FDA-approved treatments. “The next step is to find out if this can be replicated elsewhere,” he says. The study, sponsored by the Multidisciplinary Association for Psychedelic Studies, was the first FDA-approved trial evaluating MDMA’s therapeutic applications. Additional clinical tests examining MDMA-based treatments for PTSD are under way in Switzerland and Israel.
http://discovermagazine.com/2009/nov/20-treating-agony-with-ecstasy
--------------------------------------------------
Does not include the study cited above, but any other FDA approved clinical trial publishing results in 2010 that show theraputic benefits (not simply safety or dosage levels) will settle as YES. No studies published on FDA approved studies/no studies demonstrating theraputic benefits will settle as NO. Studies outside the US, thus not approved by the FDA will not be considered for settlement.
Settlement details:As reported by a major mainstream news source.
Forecast history %
| Yes |
| ||||
| No |
|
Question suspends in 41 weeks
- Activity: H$21,523 |
- Predictions: 34 |
Comments: 4
Get widget!Predictions (34)
aylouis
predicted No (H$50 at 38%)
pduck404
predicted Yes (H$81 at 35%)
hfl13
predicted No (H$333 at 64%)
bobyn42
predicted No (H$50 at 61%)
hindsight
predicted Yes (H$100 at 39%)Comments (4)
Stake virtual dollars on the outcomes of real news stories! Win more if you're right and climb the leaderboards Learn more...
By joining you are agreeing to our terms of service
Related Tags
Please log in or join to add a comment